Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Roche Holdings Ltd ADR (RHHBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 208,211,072
  • Shares Outstanding, K 6,815,420
  • Annual Sales, $ 56,655 M
  • Annual Income, $ 8,774 M
  • 36-Month Beta 0.65
  • Price/Sales 3.86
  • Price/Cash Flow 12.05
  • Price/Book 7.09
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 07/26/18
  • Annual Dividend & Yield 0.89 (2.92%)
  • Most Recent Dividend 0.918 on 03/15/18
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/18
See More
  • Average Estimate 1.12
  • Number of Estimates 1
  • High Estimate 1.12
  • Low Estimate 1.12
  • Prior Year N/A
  • Growth Rate Est. (year over year) -99.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.3300 +0.89%
on 09/06/18
31.1900 -1.89%
on 08/29/18
+0.0650 (+0.21%)
since 08/20/18
3-Month
26.9600 +13.50%
on 07/11/18
31.1900 -1.89%
on 08/29/18
+3.5100 (+12.96%)
since 06/20/18
52-Week
26.3000 +16.35%
on 06/08/18
32.4200 -5.61%
on 01/05/18
-1.3500 (-4.23%)
since 09/20/17

Most Recent Stories

More News
Dr. Reddy's (RDY) Presence in Generics Market Remains Strong

Dr. Reddy's has a strong hold in the generics market. New product launches, especially complex generics, are likely to drive the generics business at regular intervals.

LGND : 257.78 (-2.42%)
RDY : 36.73 (+1.46%)
GILD : 74.83 (+1.29%)
RHHBY : 30.6000 (+0.16%)
Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff

Novo Nordisk (NVO) plans to restructure and reallocate resources in its Research and Development organization and lay off 400 employees from the unit.

NVO : 47.50 (+1.06%)
LLY : 106.07 (+0.31%)
RHHBY : 30.6000 (+0.16%)
BMY : 61.75 (+1.56%)
Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern

Bayer (BAYRY) focuses on acquisitions and deals in order to boost growth as well as portfolio.

BAYRY : 22.4900 (+3.69%)
LLY : 106.07 (+0.31%)
RHHBY : 30.6000 (+0.16%)
BMY : 61.75 (+1.56%)
Pfizer's Skin Disease Candidates Positive in Mid-Stage Study

Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study.

JNJ : 141.98 (+1.08%)
ABBV : 92.68 (+1.82%)
RHHBY : 30.6000 (+0.16%)
PFE : 43.75 (+1.13%)
Is Artificial Intelligence the Next Big Thing in Biotech?

Artificial intelligence can drastically reduce the time taken to develop new life-saving drugs.

AZN : 37.72 (+1.13%)
JNJ : 141.98 (+1.08%)
NVS : 85.97 (+1.26%)
RHHBY : 30.6000 (+0.16%)
GSK : 39.87 (+0.81%)
PFE : 43.75 (+1.13%)
SNY : 44.15 (+0.57%)
Roche's Child Arthritis Drug's New Formulation Gets FDA Nod

Roche (RHHBY) gets FDA approval for the subcutaneous formulation of Actemra for the treatment of active systemic juvenile idiopathic arthritis in patients aged two years or older.

LLY : 106.07 (+0.31%)
ABBV : 92.68 (+1.82%)
RHHBY : 30.6000 (+0.16%)
BMY : 61.75 (+1.56%)
AstraZeneca's Lumoxiti Gets FDA Nod for Hairy Cell Leukemia

AstraZeneca's (AZN) rare blood cancer candidate receives approval from the FDA for relapsed or refractory hairy cell leukemia (HCL) in patients who have received at least two prior systemic therapies.

AZN : 37.72 (+1.13%)
MRK : 70.78 (+1.14%)
LLY : 106.07 (+0.31%)
RHHBY : 30.6000 (+0.16%)
The Zacks Analyst Blog Highlights: Oracle, Roche, Goldman Sachs, Capital One and Intercontinental Exchange

The Zacks Analyst Blog Highlights: Oracle, Roche, Goldman Sachs, Capital One and Intercontinental Exchange

ORCL : 50.43 (+2.02%)
ICE : 77.68 (+0.13%)
COF : 99.26 (+0.30%)
RHHBY : 30.6000 (+0.16%)
GS : 237.40 (+0.77%)
Top Research Reports for Oracle, Roche & Goldman Sachs

Top Research Reports for Oracle, Roche & Goldman Sachs

PLD : 67.36 (+2.14%)
ORCL : 50.43 (+2.02%)
ICE : 77.68 (+0.13%)
COF : 99.26 (+0.30%)
RHHBY : 30.6000 (+0.16%)
GS : 237.40 (+0.77%)
AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia

AbbVie (ABBV) gets FDA approval to include MRD-negativity (undetectable disease) data from phase III MURANO study on the label of Venclexta.

LLY : 106.07 (+0.31%)
ABBV : 92.68 (+1.82%)
TEVA : 24.83 (+0.77%)
RHHBY : 30.6000 (+0.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade RHHBY with:

Key Turning Points

2nd Resistance Point 30.7167
1st Resistance Point 30.6333
Last Price 30.6000
1st Support Level 30.4033
2nd Support Level 30.2567

See More

52-Week High 32.4200
Last Price 30.6000
Fibonacci 61.8% 30.0822
Fibonacci 50% 29.3600
Fibonacci 38.2% 28.6378
52-Week Low 26.3000

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar